By Andrew Pollack Hikma Pharmaceuticals agreed to pay about $2.65 billion in cash and shares for Boehringer Ingelheim’s generic drugs business in the United States. Boehringer Ingelheim said ...

The CEO of pharmaceuticals giant Roche said authorities should block the takeover of contract drug manufacturer Catalent by ...

The Biden administration has reformed Medicare, gone after bogus drug patents and pushed pharmaceutical companies to reduce ...

Denmark's Zealand Pharma and German partner Boehringer Ingelheim have won the U.S. Food and Drug Administration's ...

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare ...

The Catalysis group at Boehringer Ingelheim works with various internal and external partners to develop synthetic technologies that speed up the delivery of lifesaving drugs to patients. The webinar ...

As Hurricane Milton made landfall in Florida Wednesday night, drugmakers, regulators, hospitals and health agencies alike ...

CHICAGO -- An artificial intelligence (AI)-based study of home monitoring for neovascular age-related macular degeneration ...

AstraZeneca is capping out-of-pocket costs for inhalers and related medication at no more than $35 per month, the drugmaker ...

An interim analysis from a long-term open-label extension study has underlined the clinical efficacy and safety of ...

Boehringer's Jardiance group of products ... Biocon Biologics announced on Monday has been made available in the United States. Hulio will be offered for a list price that is 5% less than ...